DS3790a

PreclinicalSmall molecule

Daiichi Sankyo

DS3790a is one of 6 small molecule programs targeting Hematological Malignancies. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematological MalignanciesRecruiting

Hematological MalignanciesPreclinical

Recruiting

Competition

Competitive Landscape

6 competitors in Hematological Malignancies

#DrugCompanyPhaseTrials

TALVEY

Johnson & Johnson

Phase 2

2 2

Tecvayli

Johnson & Johnson

Phase 2

2 3

Omidubicel

NNational Heart, Lung, and Blood Institute (NHLBI)

Phase 3

1 4

Xospata

Astellas

Preclinical

1 5

Combination Drug

Bayer

Preclinical

1 6

DS3790a

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

PreclinicalRecruiting

Hematological Malignancies

NCT07220616

Clinical

Trials by Indication[1]

Hematological Malignancies1 trial

A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC Targeting CD37, for Hematological Malignancies

Recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Preclinical·NCT07220616·420 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DS3790a. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DS3790a compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DS3790a. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Daiichi Sankyo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Daiichi Sankyo

DS3790a

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Hematological Malignancies1 trial

References

Drug Info

Quick Facts

Related News